Paper Details

  1. Home
  2. Paper Details

ROSEWOOD: A Phase II Randomized Study of Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma.

Author: AssoulineSarit E, AuerRebecca, BijouFontanet, BouabdallahKrimo, De OliveiraAna C, DelarueRichard, FlowersChristopher R, GanlyPeter, HuangSha, IvanovaElena, JohnsonRoderick, KimPil, KingsleyEdwin, Martín García-SanchoAlejandro, MayerJiří, MerliMichele, Provencio PullaMariano, SongYuqin, TillyHerve, TrněnýMarek, TrotmanJudith, TumyanGayane, YuenSam, ZhangHuilai, ZhangQingyuan, ZinzaniPier Luigi

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

The ROSEWOOD study, a phase II, randomized trial, evaluates the efficacy and safety of zanubrutinib plus obinutuzumab (ZO) versus obinutuzumab alone in patients with relapsed/refractory follicular lymphoma (FL).
Paper Details　
Original Abstract of the Article :
The combination of zanubrutinib plus obinutuzumab (ZO) was found to be well tolerated with an early signal of efficacy in a phase Ib study. ROSEWOOD is a phase II, randomized study that assessed the efficacy and safety of ZO versus obinutuzumab in patients with relapsed/refractory (R/R) follicular l...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1200/JCO.23.00775

データ提供：米国国立医学図書館（NLM）

Zanubrutinib Plus Obinutuzumab: A Promising Combination Therapy for Follicular Lymphoma

[Follicular lymphoma] is a type of [non-Hodgkin lymphoma] that can be challenging to treat. This study investigates the [efficacy and safety] of [zanubrutinib plus obinutuzumab] in patients with [relapsed or refractory follicular lymphoma (FL)]. The authors found that [this combination therapy was well tolerated and showed early signs of efficacy]. This research provides promising results for [improving treatment outcomes] for patients with FL.

The Importance of Combination Therapies

[Combination therapies] are often used to [target multiple pathways] involved in cancer growth and spread. This research explores the potential of [zanubrutinib plus obinutuzumab] as a [promising combination therapy] for FL, offering hope for [improved treatment outcomes].

Living with Lymphoma

[Lymphoma] is a type of cancer that affects the lymphatic system. It is important to [seek medical attention] if you experience [unexplained swelling, fatigue, weight loss, or other concerning symptoms]. Your doctor can [order appropriate tests] to determine the underlying cause and recommend the [most effective treatment] for your specific condition.

Dr.Camel's Conclusion

The fight against cancer is a long and challenging journey, like a camel traversing a vast and unforgiving desert. This research offers hope for patients with follicular lymphoma by exploring the potential of zanubrutinib plus obinutuzumab as a promising combination therapy. As we continue to advance our understanding of cancer biology, we can develop more targeted and effective treatments that offer greater hope for patients.
Date :
  1. Date Completed n.d.
  2. Date Revised 2023-11-15
Further Info :

Pubmed ID

37506346

DOI: Digital Object Identifier

10.1200/JCO.23.00775

Related Literature

Article Analysis
・Effects of zanubrutinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.